The 19 references in paper D. Romodanovsky P., D. Goryachev V., A. Solovieva P., I. Kokin V., N. Eremenko N., Д. Ромодановский П., Д. Горячев В., А. Соловьева П., И. Кокин В., Н. Еременко Н. (2018) “ЭКСПЕРТНЫЕ ПОДХОДЫ К ОЦЕНКЕ ЭКВИВАЛЕНТНОСТИ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ, ЯВЛЯЮЩИХСЯ АНАЛОГАМИ ЭНДОГЕННЫХ СОЕДИНЕНИЙ, В РАМКАХ РОССИЙСКОГО ЗАКОНОДАТЕЛЬСТВА И МЕЖДУНАРОДНОГО ПРАВА // EXPERT APPROACHES TO EQUIVALENCE EVALUATION OF DRUGS — ANALOGUES OF ENDOGENOUS COMPOUNDS AS CONSISTENT WITH THE RUSSIAN LEGISLATION AND INTERNATIONAL LAW” / spz:neicon:vedomostincesmp:y:2018:i:1:p:6-10

1
Федеральный закон Российской Федерации от 12 апреля 2010 г. No 61-ФЗ «Об обращении лекарственных средств». [Federal Law of the Russian Federation of 12.04.2010, No. 61-FZ «On Circulation of Medicines» (In Russ.)] Available from: http://www.consultant.ru/ document/cons_doc_LAW_99350
(check this in PDF content)
2
Разработка гармонизированных с международными нормами и подходами научных и технических руководств в сфере обращения лекарственных средств, в том числе по разработке и исследованиям лекарственных средств. Отчет о НИР (промежуточный). ФГБУ «НЦЭСМП» Минздрава России; рук.: Олефир ЮВ, Меркулов ВА; исполн.: Бондарев ВП, Васильев АН. М.; 2015.
(check this in PDF content)
3
1 с. No ГР 115111740006. Деп. в ЦИТИС 16.02.2016, No ИКРБС 216021650026. [Development of scientific and technical guidelines harmonized with international norms and approaches in the field of medicinal products circulation, including the development and research of medicinal products. Research report (intermediate). FSBI «SCEEMP» of the Ministry of Health of Russia; advisors: Olefir YuV, Merkulov VA; prepared by: Bondarev VP, Vasiliev AN. Moscow; 2015. 341 p. No. SR 115111740006. Deposited in CITIS on 16.02.2016, No. IKRBS 216021650026 (In Russ.)] 3. Разработка и совершенствование научно-методических критериев экспертной оценки, стандартизации и принципов планирования, проведения и оформления результатов исследований отдельных групп лека
(check this in PDF content)
4
Солдатов АА, Авдеева ЖИ, Алпатова НА, Медуницын НВ, Киселевский МВ, Лысикова СЛ. и др. Проблемы регистрации биологических неоригинальных лекарственных препаратов. БИОпрепараты. Профилактика, диагностика, лечение 2014; (4): 24–36. [Soldatov AA, Avdeeva ZhI, Alpatova NA, Medunitsyn NV, Kiselevsky MV, Lysikova SL, et al. Problems of registration of biological non-original drugs. BIOpreparations. Prevention, Diagnosis, Treatment 2014; (4): 24–36 (In Russ.)]
(check this in PDF content)
5
Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA. United States Food and Drug Administration. Available from: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM377465.pdf
(check this in PDF content)
6
Draft Guidance on Progesterone. United States Food and Drug Administration. Available from: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM209294.pdf
(check this in PDF content)
7
Draft Guidance on Ethinyl Estradiol; Norethindrone. United States Food and Drug Administration. Available from: https://www.fda. gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM199639.pdf
(check this in PDF content)
8
Draft Guidance on Prednisolone Sodium Phosphate. United States Food and Drug Administration. Available from: https://www.fda.gov/ downloads/Drugs/.../Guidances/ucm089506.pdf
(check this in PDF content)
9
Guidance on Testosterone. United States Food and Drug Administration. Available from: https://www.fda.gov/downloads/ Drugs/.../Guidances/ucm090592.pdf
(check this in PDF content)
10
Draft Guidance on Levothyroxine Sodium. United States Food and Drug Administration. Available from: https://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM428208.pdf
(check this in PDF content)
11
Potassium Chloride Modified-Release Tablets and Capsules: In Vivo Bioequivalence and In Vitro Dissolution Testing. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Available from: https://www. fda.gov/ohrms/dockets/98fr/02d-0307-gdl0002.pdf
(check this in PDF content)
12
Меркулов ВА, Бунятян НД, Переверзев АП. Надлежащая практика фармаконадзора в США и Европейском Союзе. Безопасность и риск фармакотерапии 2014; (4): 23–8. [Merkulov VA, Bunyatyan ND, Pereverzev AP. Good Pharmacovigilance Practice in the United States and the European Union. Safety and Risk of Pharmacotherapy 2014; (4): 23–8 (In Russ.)]
(check this in PDF content)
13
Investigation of bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1). European Medicines Agency. Available from: http://www.ema.europa. eu/docs/en_GB/document_library/Scientific_guideline/2010/01/ WC500070039.pdf
(check this in PDF content)
14
Правила проведения исследований биоэквивалентности лекарственных средств Евразийского экономического союза. [Rules for bioequivalence studies of drugs of the Eurasian Economic Union (In Russ.)] Available from: http:// www.eurasiancommission.org/ru/act/texnreg/deptexreg/ konsultComitet/Documents/%D0%9F%D1%80%D0%B0%D0%B2 %D0%B8%D0%BB%D0%B0%20%D0%91%D0%AD%D0%98%20 %D0%B8%D1%82%D0%BE%D0%B3%2020.02.2015%20 %D0%BD%D0%B0%20%D1%81%D0%B0%D0%B9%D1%82.pdf
(check this in PDF content)
15
Dissanayake S. Assessing the bioequivalence of analogues of endogenous substances («endogenous drugs»): considerations to optimize study design. Br J Clin Pharmacol. 2010; 69(3): 238–44.
(check this in PDF content)
16
Хохлов АЛ, Лилеева ЕГ, Синицина ОА, Спешилова СА, Демарина СМ, Шитов ЛН. Проблемы проведения биоаналитической части исследований биоэквивалентности лекарственных препаратов в России. Фармакокинетика и фармакодинамика 2014; (1): 37–43. [Khokhlov AL, Lileeva EG, Sinitsina OA, Speshilova SA, Demarin SM, Shitov LN. Problems of bioanalytical research of bioequivalence of drugs in Russia. Pharmacokinetics and Pharmacodynamics 2014; (1): 37–43 (In Russ.)]
(check this in PDF content)
17
Ewerth S, Angelin B, Einarsson K, Nilsell K, Bjorkhem I. Serum concentrations of ursodeoxycholic acid in portal venous and systemic venous blood of fasting humans as determined by isotope dilutionmass spectrometry. Gastroenterology 1985; 88: 126–33.
(check this in PDF content)
18
Жердев ВП, Колыванов ГБ, Литвин АА, Сариев АК. Гармонизация проведения исследований биоэквивалентности лекарственных препаратов: вопросы и их возможное решение. Экспериментальная и клиническая фармакология 2003; 66(2): 60–4. [Zherdev VP, Kolyvanov GB, Litvin AA, Sariev AK. Harmonization of research on bioequivalence of drugs: questions and their possible solution. Experimental and Clinical Pharmacology 2003; 66(2): 60–4 (In Russ.)]
(check this in PDF content)
19
Романов БК, Олефир ЮВ, Меркулов ВА, Пегова ЮО. Пересмотр ограничительных перечней лекарственных средств. Безопасность и риск фармакотерапии 2016; (1): 5–9. [Romanov BK, Olefir YuV, Merkulov VA, Pegova YuO. Revision of restrictive lists of medicines. Safety and risk of pharmacotherapy 2016; (1): 5–9 (In Russ.)]
(check this in PDF content)